Neogene Therapeutics, Inc. (Neogene), a global clinical-stage biotechnology company pioneering the discovery, development and manufacturing of next-generation T-cell receptor therapies (TCR-Ts), today announced it has entered into a definitive agreement to be acquired by AstraZeneca. With a shared goal of bringing cell therapies to patients with solid tumors, Neogene’s expertise in TCR-T discovery, development and manufacturing will strengthen AstraZeneca’s ambition to transform outcomes for patients.
Read the full article: AstraZeneca to Acquire Neogene Therapeutics, Accelerating Ambition in Oncology Cell Therapy //
Source: https://www.businesswire.com/news/home/20221128005852/en/AstraZeneca-to-Acquire-Neogene-Therapeutics-Accelerating-Ambition-in-Oncology-Cell-Therapy